Efficiencies for patient identification in external comparators to accelerate programs and minimize patient matching inefficiencies, especially for large disease franchises.

Establishing ethical, compliant off-label observatories for precision medicines to assess clinical benefits and risks.

Adapting Mendelian randomization methods to study somatic mutations' impact on cancer treatment response using real-world data.

Coordinating biobanks to form extensive multi-center sample cohorts for translational research and diagnostic development.

Validating digital therapeutics and remote patient monitoring through real-world data, addressing confounders like patient motivation bias.

Designing and gaining regulatory acceptance for pragmatic, fully digital platform trials, with a focus on conditions like Cachexia.

Developing cost-effective digital tools suitable for an international network operating at a "regulatory grade", encompassing data models, capture innovation, outcome validation, NLP, and PRO development.